Ixekizumab

Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A (KD[1][2].

Product Specifications

CAS Number

[1143503-69-8]

Product Name Alternative

LY2439821

UNSPSC

12352203

Target

Interleukin Related

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/ixekizumab.html

Purity

99.00

Solubility

H2O

Smiles

[Ixekizumab]

Molecular Weight

(146.44 kDa)

References & Citations

[1]Liu L, et al. Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. J Inflamm Res. 2016;9:39-50. Published 2016 Apr 19.|[2]Griffiths CE, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3) : results from two phase 3 randomised trials. Lancet. 2015;386 (9993) :541-551.